It's been two weeks since Turing CEO Martin Shkreli announced he would scale back the price of his drug, and so far nothing has really changed.
The biotech leader came under fire last month for his 5,000% price hike of Daraprim, a drug that fights parasitic infections.
The biotech leader came under fire last month for his 5,000% price hike of Daraprim, a drug that fights parasitic infections.
